NEW YORK (GenomeWeb News) – Agilent Technologies today announced a deal with BioDiscovery allowing that firm's customers access to Agilent SureFISH probes directly from BioDiscovery's Nexus software.

The deal allows researchers who use different cytogenetic microarray platforms to now quickly identify aberrations with Nexus and to immediately identify and link to available oligonucleotide-based fluorescent in situ hybridization probes for follow-up studies, Agilent said.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.